MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
BCL6 rearrangement	Diffuse Large B Cell Lymphoma	BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
BCL6 rearrangement	Lymphoma	BCL6 rearrangement	Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
BCL6 translocation	Diffuse Large B Cell Lymphoma	BCL6 translocation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC translocation + BCL6 translocation	Diffuse Large B Cell Lymphoma	MYC translocation + BCL6 translocation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
BCL6 translocation	Non-Hodgkin’s Lymphoma	BCL6 translocation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
MYC translocation + BCL6 translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	MYC translocation + BCL6 translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL6 rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement + BCL6 rearrangement	Non-Hodgkin’s Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3

BCL6 (B-cell CLL/lymphoma 6)

Associations(29)

Associations
(29)